Status:
COMPLETED
Real-life Use of Niraparib in a Patient Access Program in Norway
Lead Sponsor:
Kristina Lindemann
Collaborating Sponsors:
University Hospital of North Norway
St. Olavs Hospital
Conditions:
Ovarian Cancer
Peritoneal Cancer
Eligibility:
FEMALE
Brief Summary
Retrospective observational study of patients treated with niraparib in an individual patient access program in Norway.
Detailed Description
Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as new treatment options in ovarian cancer. While there is now also evidence for the efficacy in the first line setting, they were initially...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients enrolled in the individual patient access program since 2017.
- Patients who have received at least one dose of niraparib will be included.
- Patients will be identified and recruited from the following participating sites: Oslo University Hospital, Haukeland University Hospital, Stavanger University Hospital, St. Olavs Hospital, University Hospital of Northern Norway and Sørlandet sykehus.
Exclusion
Key Trial Info
Start Date :
July 31 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 3 2020
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT04785716
Start Date
July 31 2017
End Date
August 3 2020
Last Update
March 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oslo University Hospital (OUH)
Oslo, Norway, 0379